(Bloomberg) — Eli Lilly & Co. (LLY) accredited a program to purchase again as a lot as $15 billion of its personal shares amid fast progress fueled partly by the blockbuster weight-loss drug Zepbound.
Most Learn from Bloomberg
The corporate additionally raised its quarterly dividend 15%, in accordance with a press release Monday. The shares rose as a lot as 1.3% in late buying and selling after the US markets closed.
The share repurchases could also be made occasionally at administration’s discretion, Lilly stated.
Most Learn from Bloomberg Businessweek
©2024 Bloomberg L.P.
